SERA SERA PROGNOSTICS, INC.
Healthcare · Services-Medical Laboratories
SERA PROGNOSTICS, INC. (SERA) is a healthcare company in the Services-Medical Laboratories industry, with a market capitalization of $90 million. Shares last traded at $1.80, 54.1% below their 52-week high. Over the past year the stock is down 2.7%. Net profit margin is -39417.3%, below the peer median of -8.0%. Revenue grew 5.2% year over year.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2026 | $-0.17 | 2026-05-06 |
| FY 2025 | $-0.67 | 2026-03-18 |
| Q3 2025 | $-0.51 | 2025-11-13 |
| Q2 2025 | $-0.36 | 2025-08-06 |
| Q1 2026 | $-0.20 | 2026-05-06 |
| FY 2025 | $-0.99 | 2026-03-18 |
Services-Medical Laboratories peers
SERA vs 14 industry peers (Services-Medical Laboratories), by market cap.
| NTRA | Natera, Inc. | $33.1B | -159.23 | 14.37 | -9.0% | +2.17% |
| DGX | Quest Diagnostics | $21.6B | 21.76 | 1.96 | 9.0% | -1.44% |
| LH | Labcorp | $21.0B | 23.93 | 1.50 | 6.3% | -1.40% |
| GH | Guardant Health, Inc. | $17.5B | -41.98 | 17.80 | -42.4% | +2.06% |
| CAI | Caris Life Sciences, Inc. | $5.2B | — | — | — | +3.41% |
| BLLN | Billiontoone, Inc. | $4.8B | — | — | — | +5.38% |
| VCYT | Veracyte, Inc. | $4.3B | 64.47 | 8.28 | 12.8% | +4.50% |
| CELC | Celcuity Inc. | $4.3B | -24.15 | — | — | -0.45% |
| RDNT | Radnet, Inc. | $4.2B | -226.56 | 2.07 | -0.9% | +1.83% |
| GRAL | Grail, Inc. | $2.7B | — | — | — | +7.35% |
| FTRE | Fortrea Holdings Inc. | $1.4B | — | — | — | -0.20% |
| CDNA | Caredx, Inc. | $1.4B | -63.38 | 3.56 | -5.6% | +11.89% |
| PSNL | Personalis, Inc. | $1.1B | -13.55 | — | — | +8.29% |
| LMRI | Lumexa Imaging Holdings, Inc. | $907M | — | — | — | +7.76% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.